Business Strategy
TCR App Mobility offers its core SaMD-compliant mobile application via a per-seat subscription model for B2B/G customers and pay-per-use (time-based) model for individual drivers. Our computational health diagnostic system will be licensed as a medical device software (drug discovery with pharma, corporate subscriptions and B2B2C). Together, these channels fuel a proprietary data flywheel, continuously refining our purpose-built AI algorithms.
TARGET MARKET SUMMARY
TAM | 5M companies | 1.7B people
Digital phenotyping, smart mobility, insurance risk mitigation, pharma drug discovery, predictive healthcare analytics, fleet monitoring, public administration
SAM | 1M companies | 700M people
B2B (transport, logistics, healthcare, insurance) and B2C (individual drivers) customers in Europe, United States, Canada, Australia, Japan and South Korea
SOM | 400,000 companies
Transport, mobility and logistics companies in the European Union, United Kingdom, Switzerland, Norway and Japan
INITIAL | 3,000 companies
Passenger transport companies (with at least 8 vehicles) in Poland, Slovakia, Czech Republic, Romania and Slovenia
GO-TO-MARKET STRATEGY
Beginning in 2024, our startup has been successfully building its user base in Central Europe (Poland, Slovenia, Romania, Czech Republic, Slovakia). At the present stage, we organize pilots with partners from the transport and mobility industries. We plan to acquire key B2B customers in Europe, including public transportation operators from major cities across the continent. Following this, we aim to bring our technology to the B2B user communities in East Asia (2026), India (2026/2027) and Brazil (2027/2028), consequently entering the most promising markets in terms of early adopters. We have successfully initiated the process of building strategic connections in all of these regions.
When referring to road traffic accidents prevention, our approximate B2B/G CLV amounts to €120,000. In the European Union, the total number of our potential major early adopters exceeds 80,000 entities. We project annual recurring revenue of €2.2 million in 2027, €15 million in 2029 and €95 million in 2031.
Regarding TCR App Diagnostics, our initial revenue stream will be generated through targeted recruitment of presymptomatic patients for pharma clinical trials focused on disease-modifying therapies for Parkinson's disease. Subsequently, our computational health diagnostic system will be licensed as a medical device software, with annual corporate subscriptions ranging from €25,000 to €500,000 for hospitals and specialized medical clinics. Our product is designed for prescription-based distribution, guaranteeing that every user remains under the continuous supervision of a qualified healthcare professional.
In the B2B hospital model, our CAC varies between €5,000 and €125,000 (from small clinics to large medical centres), while our average CLV reaches €800,000. Our gross margin stands at 85%. We are also able to operate within a B2B2C model, where our product is offered as a premium health-monitoring tool through private medical clinics, insurance companies and corporate wellness programs — available via prescription at an annual rate of €2,000. Our solution can be integrated into national healthcare systems, shifting the financial burden from the individual patient to institutional payers by means of public reimbursement and ensuring broad accessibility to life-saving prodromal diagnosis.